anastrozole and FMR1-Related Primary Ovarian Insufficiency studies

anastrozole and FMR1-Related Primary Ovarian Insufficiency

Research Excerpts

Excerpt	Relevance	Reference
"Women with hormone receptor (HR)-positive breast cancer who remained amenorrheic and had hormonal levels consistent with ovarian failure after adjuvant chemotherapy were enrolled in a multi-institutional clinical trial of anastrozole."	5.17	Predictors of recovery of ovarian function during aromatase inhibitor therapy. ( Banerjee, M; Gersch, C; Giacherio, D; Hayes, DF; Henry, NL; McConnell, D; Partridge, AH; Pearlman, M; Schott, AF; Stearns, V; Xia, R, 2013)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Henry, NL	1
Xia, R	1
Banerjee, M	1
Gersch, C	1
McConnell, D	1
Giacherio, D	1
Schott, AF	1
Pearlman, M	1
Stearns, V	1
Partridge, AH	1
Hayes, DF	1

Studies

Henry, NL

Xia, R

Banerjee, M

Gersch, C

McConnell, D

Giacherio, D

Schott, AF

Pearlman, M

Stearns, V

Partridge, AH

Hayes, DF

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure[NCT00555477]	Phase 2	69 participants (Actual)	Interventional	2007-08-31	Terminated (stopped due to The study was stopped after 69 subjects were enrolled because of poor accrual.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure[NCT00555477]

Phase 2

69 participants (Actual)

Interventional

2007-08-31

Terminated (stopped due to The study was stopped after 69 subjects were enrolled because of poor accrual.)

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Number of Women Who Recover Ovarian Function Within 12 Months of Al Monotherapy

In part 1 ovarian function recurrence is defined as one estradiol value >20 pg/ml or two consecutive values >10 pg/ml. In part 2 ovarian function recurrence is defined as a >75% increase in estradiol levels over prior if prior value was 15-30 pg/ml, or one estradiol value >30 pg/ml, or three consecutive values >20 pg/ml. (NCT00555477)
Timeframe: 12 months

Intervention	participants (Number)
Anastrozole Part 1	8
Anastrozole Part 2	13

Intervention

participants (Number)

Anastrozole Part 1

Anastrozole Part 2

Trials

1 trial available for anastrozole and FMR1-Related Primary Ovarian Insufficiency

Article	Year
Predictors of recovery of ovarian function during aromatase inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal;	2013

Article

Year

Predictors of recovery of ovarian function during aromatase inhibitor therapy.

Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8

Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal;

2013